Short-term outcomes of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction: A randomized pilot study.
Am Heart JApr 28, 2026 (epub)
Clinical ResearchCardiology
Eva C I Woelders, Bahram Yosofi, Denise A M Peeters et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized pilot study evaluated the safety of ticagrelor monotherapy compared to ticagrelor plus aspirin in 200 STEMI patients after primary PCI. At 3 months, major adverse cardiac and cerebral events occurred in 3.1% of the ticagrelor group versus 2.0% in the control group, with no significant difference in ischemic events.
Key findings
- Major adverse cardiac and cerebral events occurred in 3.1% of the ticagrelor group vs 2.0% in the control group.
- Clinically relevant bleeding was observed in 4.2% of the ticagrelor group vs 8.9% in the control group.
- Clinically relevant non-access site bleeding was 2.0% in the ticagrelor group vs 7.9% in the control group.
Why it matters
Understanding the safety profile of ticagrelor monotherapy could inform treatment strategies post-PCI, particularly in reducing bleeding risks associated with dual antiplatelet therapy in STEMI patients.